Due to the increased expression of TGF-β in the patients with hypertension and CAD who underwent treatment with Atorvastatin, Losartan and Captopril, it may be concluded that the drug components lead to improvement of hypertension and CAD in the specific drug mechanisms and also indirectly via upregulation of TGF-β, which is needed to be evaluated by more clinical trial investigations. The gene discussed is TGFB1; the disease is hypertensive disorder.